Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CBIO

Catalyst Biosciences (CBIO) Stock Price, News & Analysis

Catalyst Biosciences logo

About Catalyst Biosciences Stock (NASDAQ:CBIO)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.34
$7.67
52-Week Range
N/A
Volume
32,246 shs
Average Volume
763,526 shs
Market Capitalization
$291.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.

Receive CBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalyst Biosciences and its competitors with MarketBeat's FREE daily newsletter.

CBIO Stock News Headlines

Catalyst Biosciences Inc trading halted, volatility trading pause
This document could hand you a shot at $915 every single weekend!
Something fascinating happens in the options market when most traders aren't paying attention… While everyone else collects standard daily premiums Monday through Friday... There's a special opportunity to target TRIPLE premiums just for holding positions over the weekend. Think about that... Most traders get one day's worth of premium for their trades. But by entering right before the weekend, when everything works out, you could collect THREE days worth - even though markets are closed for two of them. Thanks to a special discovery by a Wall Street legend who helped manage a $1.7 trillion firm – regular folks like you can now target extra cash from the markets on weekends… Just like he showed his small group of traders on December 20th with KO... A quick 2-minute setup Friday afternoon… Head out for the weekend... Monday morning? An extra $1,111 sitting in the account (with a $5k starting stake).
Catalyst Mutual Funds
See More Headlines

CBIO Stock Analysis - Frequently Asked Questions

Catalyst Biosciences, Inc. (NASDAQ:CBIO) posted its earnings results on Thursday, August, 17th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, meeting the consensus estimate of ($0.07).

Catalyst Biosciences shares reverse split on Monday, February 13th 2017. The 1-15 reverse split was announced on Friday, February 10th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 10th 2017. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Catalyst Biosciences investors own include Baozun (BZUN), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), Applied Genetic Technologies (AGTC), Catalyst Pharmaceuticals (CPRX), Advanced Micro Devices (AMD) and VBI Vaccines (VBIV).

Company Calendar

Last Earnings
8/17/2023
Today
5/28/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CBIO
Employees
7
Year Founded
2003

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$8.24 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$790,000.00
Price / Cash Flow
N/A
Book Value
($0.78) per share
Price / Book
N/A

Miscellaneous

Free Float
36,869,000
Market Cap
$291.29 million
Optionable
Optionable
Beta
1.05

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:CBIO) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners